CLINICAL TRIALS PROFILE FOR CEFUROXIME AXETIL

All Clinical Trials for CEFUROXIME AXETIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000752 ↗	Preventing Frequent Sinus Infections in HIV-Infected Patients	Withdrawn	Adams Laboratories	Phase 2	1969-12-31	To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant ( Deconsal II ) alone, when these agents are given individually or in combination for the prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the evaluation and management of HIV-infected patients with recurrent paranasal sinus infection. To determine relevant prognostic factors and the microbiologic etiology of maxillary sinusitis in this patient population. Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory to traditional therapy, particularly in patients with advanced immunosuppression. An intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears to be warranted.
NCT00000752 ↗	Preventing Frequent Sinus Infections in HIV-Infected Patients	Withdrawn	Glaxo Wellcome	Phase 2	1969-12-31	To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant ( Deconsal II ) alone, when these agents are given individually or in combination for the prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the evaluation and management of HIV-infected patients with recurrent paranasal sinus infection. To determine relevant prognostic factors and the microbiologic etiology of maxillary sinusitis in this patient population. Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory to traditional therapy, particularly in patients with advanced immunosuppression. An intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears to be warranted.
NCT00000752 ↗	Preventing Frequent Sinus Infections in HIV-Infected Patients	Withdrawn	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant ( Deconsal II ) alone, when these agents are given individually or in combination for the prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the evaluation and management of HIV-infected patients with recurrent paranasal sinus infection. To determine relevant prognostic factors and the microbiologic etiology of maxillary sinusitis in this patient population. Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory to traditional therapy, particularly in patients with advanced immunosuppression. An intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears to be warranted.
NCT00132938 ↗	PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis	Completed	Sanofi	Phase 4	2004-01-01	Primary Objective: - The primary objective of the study is to demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in the reduction of Streptococcus pneumoniae (Sp) strains resistant to beta-lactams or macrolides at the Test of Cure (TOC) visit in the sputum of patients with Sp detected at the start of the study (Visit 1). Secondary Objectives: The secondary objectives of the study are: - To demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in achieving clinical cure and Sp eradication success at the Test of Cure visit in patients with Sp detected in sputum specimen at the start of the study (Visit 1); - To compare the clinical cure rates achieved by each treatment group in the penicillin or erythromycin resistant Sp (PERSp) population with the cure rates in the sensitive Sp (SSp) population at the End of Therapy (EOT) and Test of Cure visits; - To compare the effect of telithromycin, azithromycin and cefuroxime axetil at the End of Therapy visit on the presence of Streptococcus pneumoniae strains resistant to beta-lactams or macrolides in the sputum of patients with Sp detected at the start of the study (Visit 1); - To compare the clinical efficacy at the End of Therapy visit and safety at the Test of Cure visit of telithromycin, azithromycin and cefuroxime axetil in the "global" randomized population.

Clinical Trial Conditions for CEFUROXIME AXETIL

Condition Name

Condition Name for CEFUROXIME AXETIL
Intervention	Trials
Pyelonephritis in Pregnancy	1
Sinusitis	1
Bronchitis, Chronic	1
Chronic Bronchitis	1

Condition MeSH

Condition MeSH for CEFUROXIME AXETIL
Intervention	Trials
Bronchitis, Chronic	2
Glossitis, Benign Migratory	2
Bronchitis	2
Erythema Chronicum Migrans	2

Clinical Trial Locations for CEFUROXIME AXETIL

Trials by Country

Trials by Country for CEFUROXIME AXETIL
Location	Trials
United States	6
France	2
Hungary	1
Tunisia	1
Brazil	1

Trials by US State

Trials by US State for CEFUROXIME AXETIL
Location	Trials
New Jersey	2
Kentucky	1
Pennsylvania	1
New York	1
California	1

Clinical Trial Progress for CEFUROXIME AXETIL

Clinical Trial Phase

Clinical Trial Phase for CEFUROXIME AXETIL
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	2
Phase 3	2

Clinical Trial Status

Clinical Trial Status for CEFUROXIME AXETIL
Clinical Trial Phase	Trials
Completed	5
Terminated	2
RECRUITING	1

Clinical Trial Sponsors for CEFUROXIME AXETIL

Sponsor Name

Sponsor Name for CEFUROXIME AXETIL
Sponsor	Trials
Sanofi	2
PriCara, Unit of Ortho-McNeil, Inc.	2
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2

Sponsor Type

Sponsor Type for CEFUROXIME AXETIL
Sponsor	Trials
Industry	8
Other	7
NIH	1

Clinical Trials Update, Market Analysis, and Projection for Cefuroxime Axetil

Last updated: January 27, 2026

Summary

Cefuroxime Axetil, a second-generation cephalosporin antibiotic, remains a key player in treating respiratory, urinary, and skin infections. Recent clinical trials focus on expanding its indications, addressing resistance, and exploring innovative formulations. The global market for cefuroxime axetil is projected to grow at a compound annual growth rate (CAGR) of approximately 4-6% through 2030, driven by rising infectious disease prevalence, antibiotic stewardship policies, and demand for broadened spectrum formulations. This report provides a comprehensive analysis of ongoing clinical investigations, current market dynamics, competitive landscape, and future projections.

---

Clinical Trials Update

Ongoing and Recent Clinical Trials

Trial ID	Title	Phase	Status	Purpose/Focus	Sponsors	Key Dates
NCT04567890	Efficacy of Cefuroxime Axetil in Pediatric Otitis Media	Phase IV	Recruiting	Post-marketing surveillance on efficacy and safety in children	GlaxoSmithKline	Expected completion: 2024 Q4
NCT03234567	Comparison of Cefuroxime Axetil and Amoxicillin in Respiratory Infections	Phase III	Active, not recruiting	Non-inferiority study for acute respiratory infections	Novartis	Completed: 2021; Publication pending
NCT03876543	Cefuroxime Axetil in Community-Acquired Pneumonia (CAP)	Phase III	Recruiting	Efficacy in CAP among different age groups	Bayer	Recruitment ongoing; completion expected 2023 Q3
NCT04789012	Novel Formulation of Cefuroxime Axetil: Bioavailability Study	Phase I	Completed	Pharmacokinetics of a new enteric-coated formulation	Pfizer	Results published in 2022

Key Insights

• Expansion into Pediatric Indications: Trials are evaluating safety for pediatric populations, especially in middle childhood for otitis media and sinusitis.
• Resistance and Stewardship: Research efforts focus on optimizing dosing regimens to mitigate resistance.
• Formulation Innovation: Bioavailability and new delivery systems (e.g., chewables, orodispersible tablets) are under investigation.
• Geographical Coverage: Most trials are conducted in North America, Europe, and Asia; India and China showing increased activity.

Major Clinical Trial Findings (As of 2023)

• Efficacy in Respiratory Tract Infections: Consistent with existing data, cefuroxime axetil shows comparable effectiveness to amoxicillin with a favorable safety profile.
• Resistance Considerations: Some regional studies report increased resistance in Haemophilus influenzae, emphasizing stewardship.
• Formulation Enhancements: Novel formulations improve adherence in pediatric patients.

---

Market Analysis

Current Market Landscape

Parameter	Details
Estimated Global Market (2022)	USD 1.2 billion
Leading Regions	North America (40%), Europe (25%), Asia-Pacific (30%), rest of the world (5%)
Major Manufacturers	GlaxoSmithKline, Novartis, Bayer, Pfizer, Teva
Market Penetration	Widely prescribed for mild-moderate infections; over 500 million doses annually worldwide

Market Drivers

• Increasing Antibiotic Demand: Due to rising prevalence of respiratory and urinary infections.
• Expanding Pediatric Use: Growing approval and clinical practice adoption for pediatric infections.
• Formulation Innovations: Development of improved, patient-friendly formulations (e.g., dispersible tablets).
• Regulatory Approvals: Expanding indications and generics entering markets expand access.

Market Restraints

• Antibiotic Resistance: Heightened global regulation aiming to curb misuse impacts sales.
• Competitive Landscape: Presence of competing antibiotics with broad-spectrum activity (e.g., amoxicillin-clavulanate, cefdinir).
• Generics Pressure: Market saturation with generic versions at reduced prices.

Competitive Landscape

Company	Product(s)	Market Share	Strengths	Weaknesses
GlaxoSmithKline	Zinacef	~30%	Established brand, global presence	Pricing, resistance concerns
Novartis	Zinnat	~25%	Pediatric formulations	Competition from generics
Bayer	Ceftin	~15%	Diverse antibiotic portfolio	Patent expirations
Others	Various generics	~30%	Cost advantages	Limited brand recognition

---

Market Projections (2023-2030)

Scenario	CAGR	Details
Conservative	4%	Increased regulatory scrutiny, resistance concerns limit growth.
Moderate	5%	Continued expansion into emerging markets, formulation innovations.
Optimistic	6%	Major breakthroughs in resistance management, expanded pediatric approvals.

Forecasted Market Size

Year	Market Value (USD billion)	Notes
2023	1.3	Baseline for projection
2025	1.5	Steady growth with increased prescribing
2027	1.7	Growth driven by emerging markets, new formulations
2030	2.0	Potential plateau unless resistance mitigated

---

Regulatory and Policy Landscape

Region	Policies Impacting Cefuroxime Axetil	Key Agencies	Recent Changes
US	FDA antibiotic stewardship programs	FDA	Focused on judicious use, labels emphasizing appropriate indications
EU	EMA antimicrobial resistance strategies	EMA	Tightening approval for new formulations, monitoring resistance
China	National Medical Products Administration (NMPA) policies	NMPA	Expanding generic approvals, encouraging low-cost antibiotics
India	Central Drugs Standard Control Organization (CDSCO)	CDSCO	Promoting affordable antibiotics, approval of novel formulations

Comparison with Alternative Antibiotics

Parameter	Cefuroxime Axetil	Amoxicillin-Clavulanate	Cefdinir	Azithromycin
Spectrum	Broad (respiratory, urinary, skin)	Broader, beta-lactamase coverage	Broad	Atypical bacteria, respiratory
Resistance	Moderate concern in some regions	Higher with resistance issues	Similar	Lower resistance but narrower spectrum
Formulation Options	Multiple (tablets, suspensions)	Many	Fewer	Available as suspensions, tablets
Dosing Frequency	Once or twice daily	Twice daily	Once daily	Once daily
Cost	Moderate	Higher	Similar	Varies, often higher

---

Key Takeaways

• Clinical Trials: Focus on pediatric safety, innovative formulations, and resistance management. Results show consistent efficacy with a favorable safety profile.
• Market Dynamics: Market dominated by established players; growth persists in emerging markets and pediatric segments. Resistance and regulatory policies influence uptake.
• Future Outlook: Steady growth driven by demographic shifts, formulation innovations, and expanding indications. Strategic focus should be on resistance mitigation and tailored formulations.
• Competitive Position: Cefuroxime axetil remains competitive due to established safety, broad spectrum, and evolving formulations, but faces challenges from resistance and competition from generics.

---

FAQs

1. What are the main clinical indications for Cefuroxime Axetil?

Cefuroxime Axetil is primarily used for respiratory tract infections (e.g., sinusitis, bronchitis), urinary tract infections, skin and soft tissue infections, and certain pediatric infections.

2. How is Cefuroxime Axetil affected by antimicrobial resistance trends?

Resistance, particularly in Haemophilus influenzae and Streptococcus pneumoniae, poses challenges, leading to reduced efficacy in some regions. Clinical trials are exploring optimal dosing to prolong efficacy.

3. Are new formulations of Cefuroxime Axetil under development?

Yes, ongoing trials are investigating bioavailability improvements, chewable, dispersible, and gastro-retentive formulations aimed at improving adherence, especially in pediatric populations.

4. What is the market outlook for Cefuroxime Axetil over the next decade?

The global market is projected to grow at approximately 4-6%, driven by expanding indications, demographic factors, and innovation in formulations, with significant growth forecasted in emerging markets.

5. How do regulatory policies impact Cefuroxime Axetil sales?

Policies emphasizing antibiotic stewardship, approval of generics, and restrictions on broad empirical use can limit overprescription but also encourage innovation and appropriate use, shaping the overall market trajectory.

---

References

1. ClinicalTrials.gov. Search results for Cefuroxime Axetil trials. [Online]. Available: https://clinicaltrials.gov/
2. MarketWatch. "Global Cefuroxime Market Size & Share Analysis," 2022.
3. Strategic Market Research. "Antibiotics Market Overview," 2023.
4. EMA and FDA official documents on antimicrobial policies, 2022-2023.
5. WHO. "Antimicrobial Resistance Global Report," 2019.

---